The extent of tubulointerstitial inflammation is an independent predictor of renal survival in lupus nephritis.
Interstitial fibrosis
Interstitial inflammation
Lupus nephritis
Renal biopsy
Tubular atrophy
Journal
Journal of nephrology
ISSN: 1724-6059
Titre abrégé: J Nephrol
Pays: Italy
ID NLM: 9012268
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
28
11
2020
accepted:
17
02
2021
pubmed:
16
3
2021
medline:
29
1
2022
entrez:
15
3
2021
Statut:
ppublish
Résumé
Lupus nephritis (LN) is a major complication in patients with systemic lupus erythematosus (SLE). Tubulointerstitial injury is an inflammatory process that, if not attenuated, can promote renal damage. Despite this, the current 2003 ISN/RPS "glomerulocentric" classification does not include a score for tubulointerstitial injury. We sought to establish predictors for tubulointerstitial injury and to determine their influence on renal outcomes. This is a retrospective study of a cohort of 166 patients with biopsy-proven LN diagnosed in a Spanish referral center, with a median follow-up of 86 months. Chronic tubulointerstitial lesions were defined as interstitial fibrosis and tubular atrophy (IF/TA), whereas tubulointerstitial inflammation (TII) was defined as an acute interstitial lesion. Activity (0-24) and chronicity (0-12) indices were assigned. Composite outcome, defined as advanced CKD or development of kidney failure. The prevalence of tubulointerstitial lesions was 69.3%. Eighty-one of the biopsies had features of tubulointerstitial inflammation and only 6 of these 81 (7%) patients had moderate/severe tubulointerstitial inflammation. The incidence of interstitial fibrosis and tubular atrophy was 56.6%. Renal survival was shorter in patients with moderate/severe as compared with absent/mild interstitial fibrosis and tubular atrophy (median: 15-19 years, p = 0.009). In the Cox regression model, the grade of interstitial fibrosis and tubular atrophy was independently associated with shorter renal survival (hazard ratio: 3.9, 95% CI 1.4-10.5; p = 0.008) after adjusting for degree of IF/TA and hypertension or diabetes. The extent of tubulointerstitial inflammation emerged as an independent predictor of renal survival after adjusting for the grade of interstitial fibrosis and tubular atrophy and co-morbid conditions including hypertension or diabetes. Regarding disease duration at the time of renal biopsy, no significant association was found between the interstitial fibrosis and tubular atrophy groups. The results reported herein need to be validated in future studies to include also groups of patients who usually have a worse prognosis. Consensus on histological classification is needed to aid in defining prognosis.
Sections du résumé
BACKGROUND AND OBJECTIVE
OBJECTIVE
Lupus nephritis (LN) is a major complication in patients with systemic lupus erythematosus (SLE). Tubulointerstitial injury is an inflammatory process that, if not attenuated, can promote renal damage. Despite this, the current 2003 ISN/RPS "glomerulocentric" classification does not include a score for tubulointerstitial injury. We sought to establish predictors for tubulointerstitial injury and to determine their influence on renal outcomes.
METHODS
METHODS
This is a retrospective study of a cohort of 166 patients with biopsy-proven LN diagnosed in a Spanish referral center, with a median follow-up of 86 months. Chronic tubulointerstitial lesions were defined as interstitial fibrosis and tubular atrophy (IF/TA), whereas tubulointerstitial inflammation (TII) was defined as an acute interstitial lesion. Activity (0-24) and chronicity (0-12) indices were assigned.
OUTCOME
RESULTS
Composite outcome, defined as advanced CKD or development of kidney failure.
RESULTS
RESULTS
The prevalence of tubulointerstitial lesions was 69.3%. Eighty-one of the biopsies had features of tubulointerstitial inflammation and only 6 of these 81 (7%) patients had moderate/severe tubulointerstitial inflammation. The incidence of interstitial fibrosis and tubular atrophy was 56.6%. Renal survival was shorter in patients with moderate/severe as compared with absent/mild interstitial fibrosis and tubular atrophy (median: 15-19 years, p = 0.009). In the Cox regression model, the grade of interstitial fibrosis and tubular atrophy was independently associated with shorter renal survival (hazard ratio: 3.9, 95% CI 1.4-10.5; p = 0.008) after adjusting for degree of IF/TA and hypertension or diabetes.
CONCLUSIONS
CONCLUSIONS
The extent of tubulointerstitial inflammation emerged as an independent predictor of renal survival after adjusting for the grade of interstitial fibrosis and tubular atrophy and co-morbid conditions including hypertension or diabetes. Regarding disease duration at the time of renal biopsy, no significant association was found between the interstitial fibrosis and tubular atrophy groups. The results reported herein need to be validated in future studies to include also groups of patients who usually have a worse prognosis. Consensus on histological classification is needed to aid in defining prognosis.
Identifiants
pubmed: 33721269
doi: 10.1007/s40620-021-01007-z
pii: 10.1007/s40620-021-01007-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1897-1905Subventions
Organisme : Instituto de Salud Carlos III
ID : PI17/00080
Informations de copyright
© 2021. Italian Society of Nephrology.
Références
Saxena R, Mahajan T, Mohan C (2011) Lupus nephritis: current update. Arthritis Res Ther 13(5):240. https://doi.org/10.1186/ar3378
doi: 10.1186/ar3378
pubmed: 22078716
pmcid: 3308062
Bertsias GK, Tektonidou M, Amoura Z et al (2012) Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and pediatric lupus nephritis. Ann Rheum Dis 71(11):1771–1782. https://doi.org/10.1136/annrheumdis-2012-201940
doi: 10.1136/annrheumdis-2012-201940
pubmed: 22851469
Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria (2006) The American College of Rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum 54(2):421–432. https://doi.org/10.1002/art.21625
doi: 10.1002/art.21625
Parodis I, Tamirou F, Houssiau FA (2020) Prediction of prognosis and renal outcome in lupus nephritis. Lupus Sci Med 7(1):e000389. https://doi.org/10.1136/lupus-2020-000389
doi: 10.1136/lupus-2020-000389
pubmed: 32153796
pmcid: 7046967
Liu C-C, Kao AH, Manzi S, Ahearn JM (2013) Biomarkers in systemic lupus erythematosus: challenges and prospects for the future. Ther Adv Musculoskelet Dis 5(4):210–233. https://doi.org/10.1177/1759720X13485503
doi: 10.1177/1759720X13485503
pubmed: 23904865
pmcid: 3728979
Wilhelmus S, Bajema IM, Bertsias GK et al (2016) Lupus nephritis management guidelines compared. Nephrol Dial Transplant 31(6):904–913. https://doi.org/10.1093/ndt/gfv102
doi: 10.1093/ndt/gfv102
pubmed: 25920920
Giannico G, Fogo AB (2013) Lupus nephritis: is the kidney biopsy currently necessary in the management of lupus nephritis? Clin J Am Soc Nephrol 8(1):138–145. https://doi.org/10.2215/CJN.03400412
doi: 10.2215/CJN.03400412
pubmed: 22977215
Weening JJ, D’Agati VD, Schwartz MM et al (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15(2):241–250. https://doi.org/10.1097/01.asn.0000108969.21691.5d
doi: 10.1097/01.asn.0000108969.21691.5d
pubmed: 14747370
Yu F, Wu L-H, Tan Y et al (2010) Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney Int 77(9):820–829. https://doi.org/10.1038/ki.2010.13
doi: 10.1038/ki.2010.13
pubmed: 20182417
Brentjens JR, Sepulveda M, Baliah T et al (1975) Interstitial immune complex nephritis in patients with systemic lupus erythematosus. Kidney Int 7(5):342–350. https://doi.org/10.1038/ki.1975.47
doi: 10.1038/ki.1975.47
pubmed: 1094162
Petri M, Orbai A-M, Alarcón GS et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64(8):2677–2686. https://doi.org/10.1002/art.34473
doi: 10.1002/art.34473
pubmed: 22553077
pmcid: 3409311
Hsieh C, Chang A, Brandt D, Guttikonda R, Utset TO, Clark MR (2011) Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring. Arthritis Care Res 63(6):865–874. https://doi.org/10.1002/acr.20441
doi: 10.1002/acr.20441
Austin HA, Muenz LR, Joyce KM, Antonovych TT, Balow JE (1984) Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 25(4):689–695. https://doi.org/10.1038/ki.1984.75
doi: 10.1038/ki.1984.75
pubmed: 6482173
Gladman DD, Ibañez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29(2):288–291
pubmed: 11838846
Gladman D, Ginzler E, Goldsmith C et al (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39(3):363–369. https://doi.org/10.1002/art.1780390303
doi: 10.1002/art.1780390303
pubmed: 8607884
Londoño Jimenez A, Mowrey WB, Putterman C, Buyon J, Goilav B, Broder A (2018) Brief report: tubulointerstitial damage in lupus nephritis: a comparison of the factors associated with tubulointerstitial inflammation and renal scarring. Arthritis Rheumatol 70(11):1801–1806. https://doi.org/10.1002/art.40575
doi: 10.1002/art.40575
pubmed: 29851285
Rijnink EC, Teng YKO, Wilhelmus S et al (2017) Clinical and histopathologic characteristics associated with renal outcomes in lupus nephritis. Clin J Am Soc Nephrol 12(5):734–743. https://doi.org/10.2215/CJN.10601016
doi: 10.2215/CJN.10601016
pubmed: 28473317
pmcid: 5477219
Jovanovic B, Khan HN, Mowrey W, Izmirly PM, Schwartz D, Buyon JP, Putterman C, Goilav B BA. Tubulointerstitial damage is an independent predictor of end stage renal disease in lupus nephritis patients with mild to moderate renal impairment [abstract]. Arthritis Rheumatol. 2016;68(suppl). https://acrabstracts.org/abstract/tubulointerstitial-damage-is-an-independent-predictor-of-end-stage-renal-disease-in-lupus-nephritis-patients-with-mild-to-moderate-renal-impairment/ .
Clark MR, Trotter K, Chang A (2015) The pathogenesis and therapeutic implications of tubulointerstitial inflammation in human lupus nephritis. Semin Nephrol 35(5):455–464. https://doi.org/10.1016/j.semnephrol.2015.08.007
doi: 10.1016/j.semnephrol.2015.08.007
pubmed: 26573548
pmcid: 4653081
Hiramatsu N, Kuroiwa T, Ikeuchi H et al (2008) Revised classification of lupus nephritis is valuable in predicting renal outcome with an indication of the proportion of glomeruli affected by chronic lesions. Rheumatology 47(5):702–707. https://doi.org/10.1093/rheumatology/ken019
doi: 10.1093/rheumatology/ken019
pubmed: 18390590
Hill GS, Delahousse M, Nochy D, Mandet C, Bariéty J (2001) Proteinuria and tubulointerstitial lesions in lupus nephritis. Kidney Int 60(5):1893–1903. https://doi.org/10.1046/j.1523-1755.2001.00017.x
doi: 10.1046/j.1523-1755.2001.00017.x
pubmed: 11703608
Leatherwood C, Speyer CB, Feldman CH et al (2019) Clinical characteristics and renal prognosis associated with interstitial fibrosis and tubular atrophy (IFTA) and vascular injury in lupus nephritis biopsies. Semin Arthritis Rheum 49(3):396–404. https://doi.org/10.1016/j.semarthrit.2019.06.002
doi: 10.1016/j.semarthrit.2019.06.002
pubmed: 31277928
pmcid: 6888990
Fessler BJ, Alarcón GS, McGwin G et al (2005) Systemic lupus erythematosus in three ethnic groups: XVI. Association of hydroxychloroquine use with reduced risk of damage accrual. Arthritis Rheum 52(5):1473–1480. https://doi.org/10.1002/art.21039
doi: 10.1002/art.21039
pubmed: 15880829
Kasitanon N, Fine DM, Haas M, Magder LS, Petri M (2006) Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 15(6):366–370. https://doi.org/10.1191/0961203306lu2313oa
doi: 10.1191/0961203306lu2313oa
pubmed: 16830883
Schrezenmeier E, Dörner T (2020) Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol 16(3):155–166. https://doi.org/10.1038/s41584-020-0372-x
doi: 10.1038/s41584-020-0372-x
pubmed: 32034323
Pagni F, Galimberti S, Galbiati E et al (2016) Tubulointerstitial lesions in lupus nephritis: International multicentre study in a large cohort of patients with repeat biopsy. Nephrology (Carlton) 21(1):35–45. https://doi.org/10.1111/nep.12555
doi: 10.1111/nep.12555
Hill GS, Delahousse M, Nochy D et al (2000) A new morphologic index for the evaluation of renal biopsies in lupus nephritis. Kidney Int 58(3):1160–1173. https://doi.org/10.1046/j.1523-1755.2000.00272.x
doi: 10.1046/j.1523-1755.2000.00272.x
pubmed: 10972679
Lu J, Tam L-S, Lai FM-M et al (2011) Repeat renal biopsy in lupus nephritis: a change in histological pattern is common. Am J Nephrol 34(3):220–225. https://doi.org/10.1159/000330356
doi: 10.1159/000330356
pubmed: 21791918
Maria NI, Davidson A (2020) Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy. Nat Rev Rheumatol 16(5):255–267
doi: 10.1038/s41584-020-0401-9
Oliverio AL, Bellomo T, Mariani LH (2019) Evolving clinical applications of tissue transcriptomics in kidney disease. Front Pediatr 7:306. https://doi.org/10.3389/fped.2019.00306
doi: 10.3389/fped.2019.00306
pubmed: 31396499
pmcid: 6664065